Targeting tumor cell metabolism via the mevalonate pathway: Two hits are better than one

Statins are promising anticancer agents that target the mevalonate pathway. Tumor cells are sensitive to depletion of mevalonate-derived products but this activity triggers a homeostatic feedback loop that blunts statin efficacy. We showed that dipyridamole inhibits this feedback response and potent...

Descripción completa

Detalles Bibliográficos
Autores principales: Pandyra, Aleksandra, Penn, Linda Z
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2014
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4905210/
https://www.ncbi.nlm.nih.gov/pubmed/27308369
http://dx.doi.org/10.4161/23723548.2014.969133
_version_ 1782437229210107904
author Pandyra, Aleksandra
Penn, Linda Z
author_facet Pandyra, Aleksandra
Penn, Linda Z
author_sort Pandyra, Aleksandra
collection PubMed
description Statins are promising anticancer agents that target the mevalonate pathway. Tumor cells are sensitive to depletion of mevalonate-derived products but this activity triggers a homeostatic feedback loop that blunts statin efficacy. We showed that dipyridamole inhibits this feedback response and potentiates statin antitumor activity. This study identifies statins plus dypridamole as a preclinically effective combination of approved agents.
format Online
Article
Text
id pubmed-4905210
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-49052102016-06-15 Targeting tumor cell metabolism via the mevalonate pathway: Two hits are better than one Pandyra, Aleksandra Penn, Linda Z Mol Cell Oncol Commentary Statins are promising anticancer agents that target the mevalonate pathway. Tumor cells are sensitive to depletion of mevalonate-derived products but this activity triggers a homeostatic feedback loop that blunts statin efficacy. We showed that dipyridamole inhibits this feedback response and potentiates statin antitumor activity. This study identifies statins plus dypridamole as a preclinically effective combination of approved agents. Taylor & Francis 2014-12-31 /pmc/articles/PMC4905210/ /pubmed/27308369 http://dx.doi.org/10.4161/23723548.2014.969133 Text en © 2014 The Author(s). Published with license by Taylor & Francis Group, LLC http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted.
spellingShingle Commentary
Pandyra, Aleksandra
Penn, Linda Z
Targeting tumor cell metabolism via the mevalonate pathway: Two hits are better than one
title Targeting tumor cell metabolism via the mevalonate pathway: Two hits are better than one
title_full Targeting tumor cell metabolism via the mevalonate pathway: Two hits are better than one
title_fullStr Targeting tumor cell metabolism via the mevalonate pathway: Two hits are better than one
title_full_unstemmed Targeting tumor cell metabolism via the mevalonate pathway: Two hits are better than one
title_short Targeting tumor cell metabolism via the mevalonate pathway: Two hits are better than one
title_sort targeting tumor cell metabolism via the mevalonate pathway: two hits are better than one
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4905210/
https://www.ncbi.nlm.nih.gov/pubmed/27308369
http://dx.doi.org/10.4161/23723548.2014.969133
work_keys_str_mv AT pandyraaleksandra targetingtumorcellmetabolismviathemevalonatepathwaytwohitsarebetterthanone
AT pennlindaz targetingtumorcellmetabolismviathemevalonatepathwaytwohitsarebetterthanone

Ejemplares similares